Hystelica

We are a community built to understand women’s biology for safe and effective psychedelic use

28/08/2026

📣 We're hiring a Research Intern — Women & Psychedelics.

Hystelica is looking for someone to help us build a well-sourced evidence base on s*x differences in psychedelic medicine and women's health. You'll work alongside a multidisciplinary team, building frameworks, running research and creating education that actually reflects female biology.

🗓️ End Sept — end March
⏱️ 4–10 hours a week
📍 London &/OR remote
✉️ CV + cover letter (max 300 words) to [email protected]
⏳ Applications close 14 September

Ideal if you're comfortable searching and reading peer-reviewed papers. No previous publications needed — we care more about curiosity than CV length.

Tag someone who should apply. 💜

26/08/2026

Bringing the science to the dust. 🌬️

Dr Grace Blest-Hopley is heading to Burning Man, and speaking at Astral Outpost: Women and Psychedelics - Science, Stories and Embodiment. What we actually know about female biology and psychedelics, what we don't, and why the gap exists in the first place. Expect science, expect stories, expect discussion.

Tue 1st Sept, 10am - Astral Outpost 3&C ( right on the corner).
Come dusty. Bring water. Bring questions.

20/08/2026

Anorexia nervosa has one of the highest mortality rates of any psychiatric condition - and there is still no approved drug treatment for it. 🍄

A new pilot study from Imperial's Centre for Psychedelic Research, published in The British Journal of Psychiatry, is one of the largest to date in this population.

21 women with long-standing anorexia - average illness duration close to 11 years, all under specialist eating disorder care, none in remission despite previous treatment.

Three dosing sessions over six weeks: 1 mg, then 25 mg, then 25 mg of synthetic psilocybin. Each preceded by preparation and followed by integration, with around 50 hours of therapeutic contact - alongside usual treatment, not instead of it.

🔬 95.2% retention, in a condition where drop-out typically runs 20–70%.

🔬 Eating disorder symptoms improved significantly and held at six months (d = 0.98), with the biggest shifts in dietary restraint and eating concerns.

🔬 Motivation to change improved and was sustained to 12 months (d = 0.65) - participants moving toward naming the seriousness of their illness. In a condition this egosyntonic, that matters.

🔬 Psilocybin was well tolerated - side effects mostly mild to moderate.

The caveats: no control group, single-arm, unblinded to dose order, and wide variation in who maintained improvement. Outcomes can't be attributed to psilocybin alone - only to the whole protocol.

A female-only trial, in a condition that overwhelmingly affects women. Feasibility, not proof - but exactly the groundwork the larger controlled trials are built on.

Douglass HM, Spriggs MJ, Godfrey K, Danby JL, de Magalhaes FJC, Macdonald L, Alderton KL, Archer S, Ahmad K, Martell J, Frias JT, Sawicka G, Read T, Blemings A, Lafrance A, Nicholls D, Erritzoe D, Park RJ, Nutt DJ, Carhart-Harris RL. Psilocybin therapy for adult females with anorexia nervosa: pilot study. Br J Psychiatry. 2026 Jul 8:1-9. doi: 10.1192/bjp.2026.10687.

12/08/2026

✨ We're bringing Hystelica to the field — come find us at Boomtown Chapter 5: Radical Redesign ✨

Two sessions, two days, one very big question: what happens when we stop leaving women out of psychedelic science?

🎙 SOCIAL PSYCHEDELICS — panel
📅 Thursday 13th August | 5–6pm
📍 Ancient Futures, Thrutopia
Dr Grace Blest-Hopley () in conversation with Prof David Luke and Rob Coulson, hosted by Dr Martha Newson. Women and psychedelics, social connection, exceptional states, and cultural practice in retreat settings.

🔬 WOMEN AND PSYCHEDELICS: SCIENCE, STORIES AND EMBODIMENT
📅 Friday 14th August | 5.30–6.30pm
📍 The Observatory, The Retreat
The science of female biology and psychedelics — hormones, cycles, bodies — plus the stories and lived experience the data keeps missing.

Both venues are a short walk from each other. Come with questions, come with stories, come say hello 💜

30/07/2026

Have you used psych3d3lics? We want to hear from you.

We're recruiting for the Survey of Female Psych3d3lic Use - a study in collaboration with King's College London.

Most of what we know about psych3d3lics was learned from bodies that don't cycle, don't shift through perimenopause, and don't carry the hormonal variation half the population lives with. This survey is one step towards changing that.

You're who we're looking for if you:
✦ were assigned female at birth
✦ have taken a large dose of a psych3d3lic
✦ are 18 or over
✦ speak fluent English

What's involved: one online survey, 20–30 minutes. You'll answer questions about your symptoms and how psych3d3lic use has affected them.

A thank you: leave your email and you'll be entered into a prize draw for a £50 Amazon voucher.

Link in bio. Please share with anyone who fits!

21/07/2026

Just over a month on from ICPR 2026, and we're still feeling the momentum 🌿
Opening the conference with the first note on the main stage was an honour that's stayed with us. We shared Hystelica's mission, presented our proprietary data on female biology and psychedelic medicine, and met so many of the brilliant people now part of this growing community.
A belated but heartfelt thank you to the team for bringing ICPR to life - and to the entire Hystelica team who made it all possible.
A month later, the conversations haven't stopped. The 51% blind spot is closing - and we're just getting started. ✨

18/07/2026

A $1.2 billion PTSD drug is heading into Phase 3 — for a condition that affects women roughly twice as often as men. So why hasn't anyone tested how it works in the female body?
Methylone (TSND-201) triggers a simultaneous surge of serotonin, dopamine and norepinephrine — the very systems oestrogen reshapes across the menstrual cycle. In M**A, its closest pharmacological cousin, these effects run markedly stronger in females; in animal studies, removing the ovaries makes the difference disappear.
The Phase 2 results are genuinely promising. But the trial was 60% women and underpowered to ask whether the drug works the same way in them — and no s*x-stratified analysis exists.
This isn't a story about one molecule. It's a pattern. When we treat women as biologically static, the result isn't just inequity — it's compromised science.
Phase 3 can close the gap: s*x-stratified analyses, cycle phase and contraception tracked at every visit, reproductive-hormone endpoints alongside the psychiatric ones.
Women deserve to know whether a drug was developed for them — or simply assumed to work for them.
Read the full analysis → link in bio.
—
For educational purposes only; not medical advice.

13/07/2026

The recording is live.
Psychedelics & The Female Body - my conversation with on hormones, menstruation, and the research that simply doesn't exist yet.
We covered:
– How the menstrual cycle may interact with psychedelic experiences
– Why women have been left out of psychedelic research
– What we know (and don't) about hormones and these compounds
– Where the science needs to go next
If you've ever wondered why nobody can answer basic questions about psychedelics and the female body, this one's for you.
Link in bio to watch.

07/07/2026

New research from the Hystelica team, from the ALPS Conference 2025. 🌸
Does the menstrual cycle change the psychedelic experience? Our study - Mapping Psychedelic Use and Mystical Experience Across the Menstrual Cycle - is one of the first to ask.

We surveyed 52 women and measured their experiences using the Mystical Experience Questionnaire. Two things stood out:
✨ Cycle phase mattered — mood during the experience shifted across the menstrual cycle
✨ Women on hormonal contraceptives reported higher and more stable experiences than naturally cycling women

It's more evidence that women's biology can't be an afterthought in psychedelic science - and data collection is still ongoing.

Read more and see the full poster on our research page 👇
🔗 https://hystelica.com/research-2

04/07/2026

V1 - The Survey of Female Psychedelic Use - DATA COLLECTION -

We're asking the question that research has ignored for decades. 🍄🌸

Have psychedelics shaped how you move through menopause?

This is a King's College London research study — and if you're in perimenopause or post-menopause and have used psychedelics, we want to hear from you.
✅ One online survey

✅ Around 20–30 minutes

✅ Leave your email to be entered into a £50 Amazon voucher prize draw

👉 Take the survey here: surveymonkey.com/r/H3MPCQ8

Or find the link in our bio.

Address

London
SW109JJ

Telephone

+447564966273

Website

https://www.hystelica.com/

Alerts

Be the first to know and let us send you an email when Hystelica posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Hystelica:

Want your business to be the top-listed Health & Beauty Business in London?